These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15239226)

  • 21. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
    Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
    Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of daily administration period of natural alpha-interferon in patients with chronic hepatitis C.
    Toyoda H; Nakano S; Kumada T; Takeda I; Sugiyama K; Osada T; Kiriyama S
    Am J Gastroenterol; 1996 Apr; 91(4):743-7. PubMed ID: 8677941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased serum soluble IL-2 receptor levels following interferon therapy in patients with chronic hepatitis C.
    Sugimura T; Motomura S; Sakai H; Nawata H
    Hepatogastroenterology; 1999; 46(27):1827-30. PubMed ID: 10430354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effective interferon therapy for chronic hepatitis C patients with low viral loads.
    Fujiyama S; Chikazawa H; Honda Y; Tomita K
    Hepatogastroenterology; 2003; 50(51):817-20. PubMed ID: 12828092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study.
    Cornberg M; Hadem J; Herrmann E; Schuppert F; Schmidt HH; Reiser M; Marschal O; Steffen M; Manns MP; Wedemeyer H
    J Hepatol; 2006 Feb; 44(2):291-301. PubMed ID: 16360972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A trial of new interferon therapy for the patients with chronic hepatitis C resistant to interferon therapy].
    Arase Y; Kumada H
    Nihon Rinsho; 2001 Jul; 59(7):1309-14. PubMed ID: 11494543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection.
    Arase Y; Ikeda K; Tsubota A; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Sezaki H; Kobayashi M; Kumada H
    Intervirology; 2004; 47(6):355-61. PubMed ID: 15564748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of short-term interferon therapy for patients infected with hepatitis C virus genotype 2a.
    Tabaru A; Narita R; Hiura M; Abe S; Otsuki M
    Am J Gastroenterol; 2005 Apr; 100(4):862-7. PubMed ID: 15784033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective study of a high-intensity interferon-alpha regimen for chronic hepatitis C virus genotype 1b infection.
    Toyoda H; Kumada T; Nakano S; Takeda I; Sugiyama K; Kiriyama S; Tanikawa M; Sone Y; Hisanaga Y; Hayashi K
    Hepatogastroenterology; 2002; 49(48):1619-24. PubMed ID: 12397749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Three times weekly versus daily dose alpha-interferon treatment in patients with acute hepatitis C.
    Fabris P; Tositti G; Giordani MT; Infantolino D; de LF
    Am J Gastroenterol; 2002 Feb; 97(2):492-3. PubMed ID: 11866300
    [No Abstract]   [Full Text] [Related]  

  • 31. Tailoring interferon dose and monitoring viral load in hepatitis C virus genotype 1b infected patients: a pilot study.
    Colombatto P; Baldi M; Oliveri F; Randone A; Bonino F; Brunetto MR
    Dig Liver Dis; 2000 Apr; 32(3):211-6. PubMed ID: 10975771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intramuscular beta interferon for chronic hepatitis C: is it worth trying?
    Fesce E; Airoldi A; Mondazzi L; Maggi G; Gubertini G; Bernasconi G; Del Poggio P; Bozzetti F; Idéo G
    Ital J Gastroenterol Hepatol; 1998 Apr; 30(2):185-8. PubMed ID: 9675656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study.
    Yu ML; Dai CY; Chen SC; Lee LP; Hsieh MY; Lin ZY; Hsieh MY; Wang LY; Tsai JF; Chang WY; Chuang WL
    BMC Infect Dis; 2005 Apr; 5():27. PubMed ID: 15823212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Hepatitis C virus variability and interferon-mediated pathway inhibition].
    Fernández B; Basaras M; Blanco S; Sánchez S; Arrese E; de las Heras B; Cisterna R
    Rev Esp Quimioter; 2003 Sep; 16(3):325-9. PubMed ID: 14702125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunological response to interferon-gamma priming prior to interferon-alpha treatment in refractory chronic hepatitis C in relation to viral clearance.
    Katayama K; Kasahara A; Sasaki Y; Kashiwagi T; Naito M; Masuzawa M; Katoh M; Yoshihara H; Kamada T; Mukuda T; Hijioka T; Hori M; Hayashi N
    J Viral Hepat; 2001 May; 8(3):180-5. PubMed ID: 11380795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cryoglobulinemia in chronic hepatitis C. Improvement by alpha-interferon is independent of virus elimination].
    Glück T; Dürk H; Kötter I; Zimmermann C; Saal JG
    Med Klin (Munich); 1995 Dec; 90(12):674-80. PubMed ID: 8583982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Therapeutic progresses of hepatitis C].
    Ma QY
    Zhonghua Gan Zang Bing Za Zhi; 2003 Aug; 11(8):501-2. PubMed ID: 12939190
    [No Abstract]   [Full Text] [Related]  

  • 38. [Peripheral neuropathy during a second cycle of treatment with high doses of interferon-alpha in a patient with hepatitis C, and a review of the literature].
    Téllez-Zenteno JF; Negrete-Pulido O; Nuñez M; Estañol-Vidal B; García-Ramos G
    Rev Neurol; 2002 Oct 1-15; 35(7):644-6. PubMed ID: 12389150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Chronic viral hepatitis B and C. Hysteria and panic are no longer appropriate].
    Schwerdtfeger M; Fleig WE
    MMW Fortschr Med; 2000 Nov; 142(46):39-42. PubMed ID: 11132310
    [No Abstract]   [Full Text] [Related]  

  • 40. A case of compensated liver cirrhosis with hepatitis C virus of genotype 1b and high viral load in whom sustained virological response was achieved by 2-year administration of very low-dose recombinant interferon alpha-2b.
    Kato H; Nakamura M; Nakamura A; Ueda R
    Eur J Gastroenterol Hepatol; 2010 Jan; 22(1):121-2. PubMed ID: 19959940
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.